HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: M300179-JLR200v1 45/1/106    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lamon-Fava, S. Articles by Micherone, D. Search for Related Content PubMed PubMed Citation Articles by Lamon-Fava, S. Articles by Micherone, D. Social Bookmarking                      What's this?

Journal of Lipid Research, Vol. 45, 106-112, January 2004
Copyright © 2004 by American Society for Biochemistry and Molecular Biology

Regulation of apoA-I gene expression

Stefania Lamon-Fava¹ and Dale Micherone

Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA 02111

¹ To whom correspondence should be addressed. e-mail: stefania.lamon-fava{at}tufts.edu

We have previously shown that 17-ß-estradiol (E₂) and genistein increase the expression of apolipoprotein A-I (apoA-I), the major protein component of HDL, in Hep G2 cells. To elucidate the mechanism mediating the increase in apoA-I gene expression by these compounds, plasmid constructs containing serial deletions of the apoA-I promoter region were generated. The smallest region maintaining response to E₂ and genistein spanned the -220 to -148 sequence, and the estrogen antagonist ICI182,780 completely inhibited the E₂ and genistein effect. Nuclear extracts from cells treated with E₂ and genistein showed increased binding to site B oligonucleotide (-169 to -146), and nuclear extracts from genistein-treated cells showed increased binding to an early growth response factor 1 (Egr-1) oligonucleotide compared to control cells. An increase in the concentrations of Egr-1 and hepatocyte nuclear factor-3ß was observed in nuclear extracts of cells treated with both compounds compared to control cells. Treatment with a specific inhibitor of mitogen-activated protein (MAP) kinase, but not with other inhibitors, abolished the stimulation of apoA-I gene expression by E₂ and genistein.

These results indicate that the MAP kinase pathway is involved in the regulation of apoA-I gene expression by genistein and E₂, possibly through downstream regulation of transcription factors binding to the promoter region.

Supplementary key words apolipoprotein • liver • mitogen-activated protein kinase • early growth response factor 1 • hepatocyte nuclear factor-3ß

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. Lamon-Fava, M. R. Diffenderfer, P. H. R. Barrett, A. Buchsbaum, M. Nyaku, K. V. Horvath, B. F. Asztalos, S. Otokozawa, M. Ai, N. R. Matthan, et al. Extended-Release Niacin Alters the Metabolism of Plasma Apolipoprotein (Apo) A-I and ApoB-Containing Lipoproteins Arterioscler. Thromb. Vasc. Biol., September 1, 2008; 28(9): 1672 - 1678. [Abstract] [Full Text] [PDF]

				S. Baba, M. Natsume, A. Yasuda, Y. Nakamura, T. Tamura, N. Osakabe, M. Kanegae, and K. Kondo Plasma LDL and HDL Cholesterol and Oxidized LDL Concentrations Are Altered in Normo- and Hypercholesterolemic Humans after Intake of Different Levels of Cocoa Powder J. Nutr., June 1, 2007; 137(6): 1436 - 1441. [Abstract] [Full Text] [PDF]

				S. Baba, N. Osakabe, Y. Kato, M. Natsume, A. Yasuda, T. Kido, K. Fukuda, Y. Muto, and K. Kondo Continuous intake of polyphenolic compounds containing cocoa powder reduces LDL oxidative susceptibility and has beneficial effects on plasma HDL-cholesterol concentrations in humans Am. J. Clinical Nutrition, March 1, 2007; 85(3): 709 - 717. [Abstract] [Full Text] [PDF]

				A. D. Mooradian, M. J. Haas, and N. C. W. Wong The Effect of Select Nutrients on Serum High-Density Lipoprotein Cholesterol and Apolipoprotein A-I Levels Endocr. Rev., February 1, 2006; 27(1): 2 - 16. [Abstract] [Full Text] [PDF]

				S. Lamon-Fava, B. Postfai, M. Diffenderfer, C. DeLuca, J. O'Connor Jr, F. K. Welty, G. G. Dolnikowski, P. H. R. Barrett, and E. J. Schaefer Role of the Estrogen and Progestin in Hormonal Replacement Therapy on Apolipoprotein A-I Kinetics in Postmenopausal Women Arterioscler. Thromb. Vasc. Biol., February 1, 2006; 26(2): 385 - 391. [Abstract] [Full Text] [PDF]

				D. J. Grainger and P. M. Schofield Tamoxifen for the Prevention of Myocardial Infarction in Humans: Preclinical and Early Clinical Evidence Circulation, November 8, 2005; 112(19): 3018 - 3024. [Full Text] [PDF]